bioAffinity Technologies

Biotechnology ResearchTexas, United States11-50 Employees

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage lung cancer and other diseases of the lung. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is especially useful for patients whose lung cancer screening or other scan reveals a pulmonary nodule. 

Our first product, CyPath® Flow Cytometry for Lung Cancer (CyPath® Lung), has been licensed by Precision Pathology Services for continued development and commercial sale as a Laboratory Developed Test. 

CyPath® Lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.

Sign up for free to view info

Email Format Employee directory